MAX-ing out MYC: a novel small molecule inhibitor against MYC-dependent tumors

J Natl Cancer Inst. 2014 Nov 27;106(12):dju365. doi: 10.1093/jnci/dju365. Print 2014 Dec.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Comment

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Carcinoma, Pancreatic Ductal / drug therapy*
  • Carcinoma, Pancreatic Ductal / genetics*
  • Male
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / genetics*
  • Proto-Oncogene Proteins c-myc / antagonists & inhibitors*
  • Proto-Oncogene Proteins p21(ras) / genetics*
  • Thiazoles / pharmacology*

Substances

  • 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one
  • Antineoplastic Agents
  • Myc protein, mouse
  • Proto-Oncogene Proteins c-myc
  • Thiazoles
  • Hras protein, mouse
  • Proto-Oncogene Proteins p21(ras)